Logo image of FWBI

FIRST WAVE BIOPHARMA (FWBI) Stock Fundamental Analysis

USA - NASDAQ:FWBI - US33749P4081 - Common Stock

2.96 USD
+0.13 (+4.59%)
Last: 5/16/2024, 8:00:00 PM
Fundamental Rating

1

Overall FWBI gets a fundamental rating of 1 out of 10. We evaluated FWBI against 531 industry peers in the Biotechnology industry. FWBI has a bad profitability rating. Also its financial health evaluation is rather negative. FWBI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

FWBI had negative earnings in the past year.
In the past year FWBI has reported a negative cash flow from operations.
In the past 5 years FWBI always reported negative net income.
In the past 5 years FWBI always reported negative operating cash flow.
FWBI Yearly Net Income VS EBIT VS OCF VS FCFFWBI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -233.87%, FWBI is doing worse than 92.62% of the companies in the same industry.
FWBI has a Return On Equity of -446.80%. This is in the lower half of the industry: FWBI underperforms 78.56% of its industry peers.
Industry RankSector Rank
ROA -233.87%
ROE -446.8%
ROIC N/A
ROA(3y)-408.67%
ROA(5y)-343.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FWBI Yearly ROA, ROE, ROICFWBI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10K -20K -30K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for FWBI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FWBI Yearly Profit, Operating, Gross MarginsFWBI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

2

2. Health

2.1 Basic Checks

FWBI has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, FWBI has more shares outstanding
The debt/assets ratio for FWBI has been reduced compared to a year ago.
FWBI Yearly Shares OutstandingFWBI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M
FWBI Yearly Total Debt VS Total AssetsFWBI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -43.89, we must say that FWBI is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of FWBI (-43.89) is worse than 94.34% of its industry peers.
FWBI has a Debt/Equity ratio of 0.17. This is a healthy value indicating a solid balance between debt and equity.
FWBI's Debt to Equity ratio of 0.17 is on the low side compared to the rest of the industry. FWBI is outperformed by 66.72% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Altman-Z -43.89
ROIC/WACCN/A
WACCN/A
FWBI Yearly LT Debt VS Equity VS FCFFWBI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M

2.3 Liquidity

A Current Ratio of 1.58 indicates that FWBI should not have too much problems paying its short term obligations.
The Current ratio of FWBI (1.58) is worse than 81.13% of its industry peers.
A Quick Ratio of 1.58 indicates that FWBI should not have too much problems paying its short term obligations.
FWBI has a worse Quick ratio (1.58) than 79.59% of its industry peers.
Industry RankSector Rank
Current Ratio 1.58
Quick Ratio 1.58
FWBI Yearly Current Assets VS Current LiabilitesFWBI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

FWBI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 75.50%, which is quite impressive.
EPS 1Y (TTM)75.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.93% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y95.87%
EPS Next 2Y40.79%
EPS Next 3Y25.45%
EPS Next 5Y14.93%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
FWBI Yearly Revenue VS EstimatesFWBI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 100M 200M 300M
FWBI Yearly EPS VS EstimatesFWBI Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10K -20K -30K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FWBI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FWBI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FWBI Price Earnings VS Forward Price EarningsFWBI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FWBI Per share dataFWBI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80

4.3 Compensation for Growth

FWBI's earnings are expected to grow with 25.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.79%
EPS Next 3Y25.45%

More info and screens

0

5. Dividend

5.1 Amount

FWBI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FIRST WAVE BIOPHARMA

NASDAQ:FWBI (5/16/2024, 8:00:00 PM)

2.96

+0.13 (+4.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2024-05-12/bmo
Earnings (Next)08-14 2024-08-14/bmo
Inst Owners5.98%
Inst Owner Change-8.45%
Ins Owners10.98%
Ins Owner Change0%
Market Cap4.62M
Revenue(TTM)N/A
Net Income(TTM)-16.10M
Analysts80
Price Target36.72 (1140.54%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.66%
Min EPS beat(2)-29.99%
Max EPS beat(2)26.67%
EPS beat(4)2
Avg EPS beat(4)-16.31%
Min EPS beat(4)-78.17%
Max EPS beat(4)26.67%
EPS beat(8)4
Avg EPS beat(8)-7.61%
EPS beat(12)4
Avg EPS beat(12)-48.37%
EPS beat(16)4
Avg EPS beat(16)-53.16%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-10%
EPS NQ rev (1m)-0.62%
EPS NQ rev (3m)-6.81%
EPS NY rev (1m)0%
EPS NY rev (3m)32.61%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.28
P/tB 2.41
EV/EBITDA N/A
EPS(TTM)-88.75
EYN/A
EPS(NY)-3.67
Fwd EYN/A
FCF(TTM)-7.93
FCFYN/A
OCF(TTM)-7.93
OCFYN/A
SpS0
BVpS2.31
TBVpS1.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -233.87%
ROE -446.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-408.67%
ROA(5y)-343.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.58
Quick Ratio 1.58
Altman-Z -43.89
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)75.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.18%
EPS Next Y95.87%
EPS Next 2Y40.79%
EPS Next 3Y25.45%
EPS Next 5Y14.93%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-24.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y44.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.59%
OCF growth 3YN/A
OCF growth 5YN/A

FIRST WAVE BIOPHARMA / FWBI FAQ

What is the ChartMill fundamental rating of FIRST WAVE BIOPHARMA (FWBI) stock?

ChartMill assigns a fundamental rating of 1 / 10 to FWBI.


What is the valuation status of FIRST WAVE BIOPHARMA (FWBI) stock?

ChartMill assigns a valuation rating of 1 / 10 to FIRST WAVE BIOPHARMA (FWBI). This can be considered as Overvalued.


What is the profitability of FWBI stock?

FIRST WAVE BIOPHARMA (FWBI) has a profitability rating of 0 / 10.